Randomised, double-blind, placebo-controlled, parallel-group, multicentric, phase IIA clinical trial for evaluating the safety, tolerability, and therapeutic efficacy of daily oral administration of NFX88 to treat neuropathic pain in individuals with spinal cord injury
Open Access
- 19 June 2024
- journal article
- research article
- Published by Springer Nature in Spinal Cord
- Vol. 62 (8) , 454-467
Abstract
Study design: Double-blind, randomized, placebo-controlled, parallel-group multicentric phase IIA clinical trial. Objective: To assess the safety and tolerability of oral administration of NFX-88 in subjects with chronic spinal cord injury (SCI) and explore its efficacy in pain control. Setting: A total of 7 spinal cord injury rehabilitation units in Spain. Methods: A total of 61 adult with traumatic complete or incomplete spinal cord injury (C4-T12 level), were randomised 1:1:1:1 to a placebo, NFX88 1.05 g, 2.1 g, 4.2 g/day for up to 12 weeks. The placebo or NFX-88 was administered as add-on therapy to pre-existing pregabalin (150–300 mg per day). Safety and tolerability were evaluated, and the Visual Analogue Scale (VAS) was the primary measure to explore the efficacy of NFX-88 in pain control. Results: No severe treatment-related adverse effects were reported for any of the four study groups. 44 SCI individuals completed the study and were analysed. The data obtained from the VAS analysis and the PainDETECT Questionnaire (PD-Q) suggested that the combination of NFX88 with pregabalin is more effective than pregabalin with placebo at reducing neuropathic pain (NP) in individuals with SCI and that the dose 2.10 g/day causes the most dramatic pain relief. Conclusions: NFX88 treatment was found to be highly safe and well tolerated, with the dose of 2.10 g/day being the most effective at causing pain relief. Thus, the promising efficacy of this first-in-class lipid mediator deserves further consideration in future clinical trials.Keywords
This publication has 29 references indexed in Scilit:
- Screening tools for neuropathic pain: Can they be of use in individuals with spinal cord injury?Pain, 2011
- Synthesis of LysophospholipidsMolecules, 2010
- Neuropathic pain in spinal cord injury: Identification, classification, evaluationAnnals of Physical and Rehabilitation Medicine, 2009
- Management of neuropathic pain following spinal cord injury: now and in the futureSpinal Cord, 2008
- Symptom Burden in Persons With Spinal Cord InjuryArchives of Physical Medicine and Rehabilitation, 2007
- painDETECT: a new screening questionnaire to identify neuropathic components in patients with back painCurrent Medical Research and Opinion, 2006
- Treatments for Chronic Pain in Persons With Spinal Cord Injury: A Survey StudyThe Journal of Spinal Cord Medicine, 2006
- Membrane-lipid therapy: a new approach in molecular medicineTrends in Molecular Medicine, 2006
- Initiation of neuropathic pain requires lysophosphatidic acid receptor signalingNature Medicine, 2004
- Effects of IV morphine in central painNeurology, 2002